News | June 02, 2008

GE Focuses on PET-VCAR Innovations at ASCO

June 3, 2008 – GE showcased at ASCO its latest advances in molecular imaging technologies such as the IN Cell Analyzer, Positron Emission Tomography/Volume Computer Assisted Reading (PET-VCAR) and Fastlab automated PET radiopharmacy, aiming to help healthcare providers understand the molecular root of diseases and explore new paths for detecting, treating and monitoring illnesses earlier.

PET-VCAR is a complement to GE’s approach to personal patient management. The system reportedly helps optimize tumor management by enabling early quantification and evaluation of treatment effectiveness, a valuable tool for treatment planning. It features workflow enhancements for both single and multi-exam review, and includes exam-to-exam auto-registration; tumor segmentation and quantification; and multiplanar image review.

IN Cell Analyzer System from GE’s Life Science Division, represents a complete solution for high-content sub-cellular analysis. Used in research and drug discovery, the system performs assays directly inside cells and uses image analysis techniques to give quantitative results for those assays for each individual cell. The power of the IN Cell Analyzer comes from using the high throughput it delivers to analyze thousands of cells under different conditions to generate statistically robust data.

Fastlab is the first multitracer PET chemistry synthesis platform to feature a cassette that incorporates premeasured, preloaded reagents—an innovation that reportedly delivers higher yields, improved reproducibility and faster synthesis than any other platform. It is designed to accommodate different chemistries, facilitating the production of multiple PET tracers. The first application launched on the platform is FDG. GE Healthcare is planning to expand the utility of the platform by developing a range of other radiopharmaceuticals, including GE Healthcare proprietary diagnostic imaging agents.

The GE Signa Vibrant is a dedicated 1.5T breast MR scanner utilizing High Definition technology and applications specifically designed for breast MR, including: VIBRANT acquisition, BREASE spectroscopy, integrated CADstream (manufactured by Confirma) and a specially designed breast MR patient table designed to provide optimal imaging and outstanding access for intervention. Signa Vibrant’s design is said to be ideally suited for the environment of many breast-imaging centers.

GE helps physicians take aim at cancer with their Advanced Imaging technologies for radiation therapy planning. GE’s radiation therapy solutions include advanced imaging technologies with LightSpeedRT16 wide-bore multislice CT simulator, Discovery PET-CT scanner, Signa MR system and radiation oncology simulation software, providing tools geared at maximizing the potential of new treatment delivery technologies.

GE also showcased solutions from its Centricity portfolio, including the Centricity Electronic Medical Record, Practice Solution and PACS. With users reportedly ranging from the nation’s largest healthcare organization to the solo practitioner, the Centricity EMR is an ambulatory system relied on by more than 30,000 clinicians nationwide. Centricity Practice Solution is a completely integrated clinical and financial management solution aimed to provide a singular approach to a more efficient, high quality practice – extending from the patient’s first visit to final reimbursement.

For more information: www.gehealthcare.com

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
PET
Feature | Imaging | April 11, 2017 | By Greg Freiherr
Positron emission tomography (PET) and other brain assessments
Overlay Init